Literature DB >> 31383670

Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.

Kalisvar Marimuthu1,2,3, Oon Tek Ng4,2,5, Benjamin Pei Zhi Cherng3,6,7, Raymond Kok Choon Fong8, Surinder Kaur Pada9, Partha Pratim De10, Say Tat Ooi11, Nares Smitasin3,12, Koh Cheng Thoon3,5,7,13, Prabha Unny Krishnan5,10,14, Michelle Lay Teng Ang14, Douglas Su Gin Chan15, Andrea Lay Hoon Kwa7,16, Rama Narayana Deepak17, Yu Kit Chan4,2, Yvonne Fu Zi Chan6, Xiaowei Huan2, Kyaw Zaw Linn2, Nancy Wen Sim Tee18, Thean Yen Tan19, Tse Hsien Koh7,20, Raymond Tzer Pin Lin14,18,21, Li Yang Hsu4,2,22, Sharmila Sengupta2, David L Paterson23, Eli Perencevich24, Stephan Harbarth25, Jeanette Teo18, Indumathi Venkatachalam6.   

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) can be mechanistically classified into carbapenemase-producing Enterobacteriaceae (CPE) and non-carbapenemase-producing carbapenem nonsusceptible Enterobacteriaceae (NCPCRE). We sought to investigate the effect of antecedent carbapenem exposure as a risk factor for NCPCRE versus CPE. Among all patients with CRE colonization and infection, we conducted a case-control study comparing patients with NCPCRE (cases) and patients with CPE (controls). The presence of carbapenemases was investigated with phenotypic tests followed by PCR for predominant carbapenemase genes. We included 843 unique patients with first-episode CRE, including 387 (45.9%) NCPCRE and 456 (54.1%) CPE. The resistance genes detected in CPEs were bla NDM (42.8%), bla KPC (38.4%), and bla OXA-48-like (12.1%). After adjusting for confounders and clustering at the institutional level, the odds of prior 30-day carbapenem exposure was three times higher among NCPCRE than CPE patients (adjusted odds ratio [aOR], 3.48; 95% confidence interval [CI], 2.39 to 5.09; P < 0.001). The odds of prior carbapenem exposure and NCPCRE detection persisted in stratified analyses by Enterobacteriaceae species (Klebsiella pneumoniae and Escherichia coli) and carbapenemase gene (bla NDM and bla KPC). CPE was associated with male gender (aOR, 1.45; 95% CI, 1.07 to 1.97; P = 0.02), intensive care unit stay (aOR, 1.84; 95% CI, 1.24 to 2.74; P = 0.003), and hospitalization in the preceding 1 year (aOR, 1.42; 95% CI, 1.01 to 2.02; P = 0.05). In a large nationwide study, antecedent carbapenem exposure was a significant risk factor for NCPCRE versus CPE, suggesting a differential effect of antibiotic selection pressure.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  carbapenem resistance; carbapenem-resistant Enterobacteriaceaezzm321990; carbapenemase-producing Enterobacteriaceaezzm321990; risk factors

Mesh:

Substances:

Year:  2019        PMID: 31383670      PMCID: PMC6761519          DOI: 10.1128/AAC.00845-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Infection control implications of heterogeneous resistance mechanisms in carbapenem-resistant Enterobacteriaceae (CRE).

Authors:  K E Goodman; P J Simner; P D Tamma; A M Milstone
Journal:  Expert Rev Anti Infect Ther       Date:  2015-11-04       Impact factor: 5.091

2.  Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in gram-negative bacilli.

Authors:  S Harbarth; A D Harris; Y Carmeli; M H Samore
Journal:  Clin Infect Dis       Date:  2001-10-04       Impact factor: 9.079

3.  Proactive infection control measures to prevent nosocomial transmission of carbapenem-resistant Enterobacteriaceae in a non-endemic area.

Authors:  Vincent Chi-Chung Cheng; Jasper Fuk-Woo Chan; Sally Cheuk-Ying Wong; Jonathan Hon-Kwan Chen; Josepha Wai-Ming Tai; Mei-Kum Yan; Grace See-Wai Kwan; Herman Tse; Kelvin Kai-Wang To; Pak-Leung Ho; Kwok-Yung Yuen
Journal:  Chin Med J (Engl)       Date:  2013-12       Impact factor: 2.628

4.  Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case-control study.

Authors:  G B Orsi; A Bencardino; A Vena; A Carattoli; C Venditti; M Falcone; A Giordano; M Venditti
Journal:  Infection       Date:  2012-10-16       Impact factor: 3.553

5.  Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients.

Authors:  Laurence Armand-Lefèvre; Cécile Angebault; François Barbier; Emilie Hamelet; Gilles Defrance; Etienne Ruppé; Régis Bronchard; Raphaël Lepeule; Jean-Christophe Lucet; Assiya El Mniai; Michel Wolff; Philippe Montravers; Patrick Plésiat; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

6.  Prevalence of Healthcare-Associated Infections and Antimicrobial Use Among Adult Inpatients in Singapore Acute-Care Hospitals: Results From the First National Point Prevalence Survey.

Authors:  Yiying Cai; Indumathi Venkatachalam; Nancy W Tee; Thean Yen Tan; Asok Kurup; Sin Yew Wong; Chian Yong Low; Yang Wang; Winnie Lee; Yi Xin Liew; Brenda Ang; David C Lye; Angela Chow; Moi Lin Ling; Helen M Oh; Cassandra A Cuvin; Say Tat Ooi; Surinder K Pada; Chong Hee Lim; Jack Wei Chieh Tan; Kean Lee Chew; Van Hai Nguyen; Dale A Fisher; Herman Goossens; Andrea L Kwa; Paul A Tambyah; Li Yang Hsu; Kalisvar Marimuthu
Journal:  Clin Infect Dis       Date:  2017-05-15       Impact factor: 9.079

7.  Using Patient Risk Factors to Identify Whether Carbapenem-Resistant Enterobacteriaceae Infections Are Caused by Carbapenemase-Producing Organisms.

Authors:  Patricia J Simner; Katherine E Goodman; Karen C Carroll; Anthony D Harris; Jennifer H Han; Pranita D Tamma
Journal:  Open Forum Infect Dis       Date:  2018-05-17       Impact factor: 3.835

8.  OXA-181-producing Klebsiella pneumoniae establishing in Singapore.

Authors:  Michelle N D Balm; Grace Ngan; Roland Jureen; Raymond T P Lin; Jeanette W P Teo
Journal:  BMC Infect Dis       Date:  2013-02-01       Impact factor: 3.090

9.  Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control.

Authors:  A P Magiorakos; K Burns; J Rodríguez Baño; M Borg; G Daikos; U Dumpis; J C Lucet; M L Moro; E Tacconelli; G Skov Simonsen; E Szilágyi; A Voss; J T Weber
Journal:  Antimicrob Resist Infect Control       Date:  2017-11-15       Impact factor: 4.887

10.  A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States.

Authors:  Daniel J Livorsi; Margaret L Chorazy; Marin L Schweizer; Erin C Balkenende; Amy E Blevins; Rajeshwari Nair; Matthew H Samore; Richard E Nelson; Karim Khader; Eli N Perencevich
Journal:  Antimicrob Resist Infect Control       Date:  2018-04-24       Impact factor: 4.887

View more
  4 in total

1.  The Clinical and Molecular Epidemiology of Noncarbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae: A Case-Case-Control Matched Analysis.

Authors:  Ruth Bouganim; Liana Dykman; Omar Fakeh; Yair Motro; Rivka Oren; Chen Daniel; Tzilia Lazarovitch; Ronit Zaidenstein; Jacob Moran-Gilad; Dror Marchaim
Journal:  Open Forum Infect Dis       Date:  2020-07-17       Impact factor: 3.835

2.  Whole-Genome Characterisation of ESBL-Producing E. coli Isolated from Drinking Water and Dog Faeces from Rural Andean Households in Peru.

Authors:  Maria Luisa Medina-Pizzali; Apoorva Venkatesh; Maribel Riveros; Diego Cuicapuza; Gabriela Salmon-Mulanovich; Daniel Mäusezahl; Stella M Hartinger
Journal:  Antibiotics (Basel)       Date:  2022-05-20

Review 3.  Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients.

Authors:  Jean-François Timsit; Paul-Henri Wicky; Etienne de Montmollin
Journal:  Antibiotics (Basel)       Date:  2022-01-24

4.  Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe.

Authors:  Dee Shortridge; Lalitagauri M Deshpande; Jennifer M Streit; Mariana Castanheira
Journal:  JAC Antimicrob Resist       Date:  2022-09-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.